All In Biotech

Drug Trial Radar · NCT06026891

Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis

Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Effectiveness and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 498 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

498

Planned (sponsor's estimate)

Start

Jan 13, 2024

Primary completion

Jun 11, 2025

Study completion Dec 12, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week

Conditions

  • Atopic Dermatitis

Interventions

  • MG-K10/PlaceboDrug

    MG-K10 Humanized Monoclonal Antibody Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportions of subjects achieving EASI-75Time frame: 16 weeks
  2. Proportions of subjects achieving IGA score of 0/1 point and a decrease of ≥ 2Time frame: 16weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.